Amy B.

Amy B. possesses extensive experience in the biopharmaceutical and life sciences sectors, currently serving on the Board of Directors for Logix Biosciences and holding the position of President at ASB Advisors. Previously, Amy was pivotal as President, Chief Strategy and Operating Officer at Qualigen Therapeutics, guiding therapeutic and diagnostic strategies. Additional roles include senior positions at Viking Therapeutics, EMD Serono, Arena Pharmaceuticals, and Medtronic, among others, where responsibilities spanned global corporate development, marketing excellence, and commercialization planning. Amy's educational background includes a Bachelor of Arts, Cum Laude, and postgraduate coursework from Fairleigh Dickinson University, complemented by studies at Wroxton College.